阿托伐他汀改善野百合碱诱导的慢性肺动脉高压大鼠肺动脉血管重塑与功能

发布时间：2018-03-15 06:27

本文选题：野百合碱　切入点：肺动脉高压　出处：《中华高血压杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的探索阿托伐他汀对20mg/kg野百合碱隔周2次腹腔注射诱导的肺动脉高压(PAH)的影响。方法雄性成年SD大鼠96只随机分为3组:空白对照组、PAH组以及阿托伐他汀组。在第0周(第1天)和第1周末(第8天)以野百合碱(20mg/kg)2次腹腔注射建立大鼠PAH模型。首次腹腔注射的同时,阿托伐他汀组大鼠通过灌胃接受10mg/(kg·d)的阿托伐他汀。第2周和第4周末分别检测平均肺动脉压(mPAP)、右心室肥厚指数(RVHI)、管壁厚度占血管外径百分比(WT%)、管壁面积占血管总面积百分比(WA%)、内皮依赖性舒张功能(EDdR)、非内皮依赖性舒张功能(EDiR)。结果野百合碱腹腔注射后第2周末,3组大鼠mPAP差异无统计学意义;在第4周末,与空白对照组比较,PAH组和阿托伐他汀组mPAP明显升高[mPAP:(33.55±3.47)、(25.46±4.04)比(18.91±2.13)mmHg],但阿托伐他汀组低于PAH组(均P0.05)。野百合碱腹腔注射后的第2周和第4周末,与空白对照组相比,PAH组和阿托伐他汀组WT%、WA%水平较高[第2周:WT%:(42.17±4.12)%、(33.83±1.23)%比(28.95±2.97)%;WA%:(65.91±4.92)%、(58.37±3.42)%比(49.08±2.84)%;第4周:WT%:(55.79±4.15)%、(40.69±2.53)%比(29.38±4.50)%;WA%:(79.75±3.30)%、(64.11±3.18)%比(49.44±6.28)%],但阿托伐他汀组低于PAH组(均P0.05)。同时,阿托伐他汀显著改善野百合碱腹腔注射后大鼠肺小动脉的EDdR和EDiR;但野百合碱腹腔注射和阿托伐他汀治疗后,血管收缩功能未发生改变。结论以20mg/kg野百合碱隔周2次腹腔注射可以建立稳定的PAH模型。阿托伐他汀通过改善肺动脉血管重塑以及血管舒张功能缓解野百合碱诱导的PAH。
[Abstract]:Objective to investigate the effect of Atto vastatin on pulmonary hypertension induced by 20 mg / kg monocrotaline twice a week. Methods 96 male adult SD rats were randomly divided into three groups: blank control group and Atto vastatin group. At week 0 (day 1) and week 1 (day 8), the rat PAH model was established by intraperitoneal injection of monocrotaline 20 mg / kg. In the Atto vastatin group, Atto vastatin (10 mg / kg 路d) was administered intragastrically. Mean pulmonary artery pressure (MPP), right ventricular hypertrophy index (RVHIV), wall thickness as a percentage of vascular diameter were measured at the 2nd week and 4th week, respectively, and the wall area accounted for the total blood vessel. There was no significant difference in mPAP between the three groups at the end of the second week after intraperitoneal injection of monocrotaline. At the end of the 4th week, compared with the blank control group, the mPAP in the PAH group and the Atto vastatin group was significantly increased [mPAP:(33.55 卤3.47 + 4.04] compared with 18.91 卤2.13 mmHg, but the Atto vastatin group was lower than that in the PAH group (P 0.05). The second week and the fourth week after intraperitoneal injection of monocrotaline, there was no significant difference between the two groups. Compared with the blank control group, the WTO WA% level in the PAH group and the Atto vastatin group was higher [WT: 42.17 卤4.1223% in the second week was 33.83 卤1.23% vs 28.95 卤2.97% in the control group, and 58.37 卤3.42% in the PAH group and 58.37 卤3.42% in the Atto vastatin group compared with 49.08 卤2.84% in the control group; in the 4th week, the WTO: 55.79 卤4.15% was higher than 29.38 卤4.50% in the second week [79.75 卤3.3030% 卤64.11 卤3.18% vs 49.44 卤6.28%], but in the Atto group, it was lower than that in the PAH group (P 0.055.59 卤2.53% vs 29.38 卤4.50% vs 29.38 卤4.50% vs 64.11 卤3.18% vs 49.44 卤6.28%). Atto vastatin significantly improved EDdR and Edir of pulmonary arterioles in rats after intraperitoneal injection of monocrotaline, but after intraperitoneal injection of monocrotaline and Atto vastatin, Conclusion the stable PAH model can be established by intraperitoneal injection of 20 mg / kg monocrotaline every other week. Atto vastatin alleviates monocrotaline induced PAHs by improving pulmonary artery remodeling and vasodilation.
【作者单位】：福建医科大学附属第一医院福建省高血压研究所;
【分类号】：R-332;R544.1

【参考文献】